"id","substantialImpact","instanceType","number","uuid:ID","summary"
"StudyAmendment_1","True","StudyAmendment","A","d241798c-e663-4a92-9142-e4b42fc389af","<p>Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus has been amended. The new protocol is indicated by Amendment (a) and will be used to conduct the study in place of any preceding version of the protocol.</p>
<p>The overall changes and rationale for the changes made to this protocol are as follows:</p>
<ul>
  <li>An exclusion criterion for patients with retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage induced by hypoglycemia.</li>
  <li>The GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary of Product Characteristics (2015).</li>
</ul>"
